biostudies-literatureMcCahill LENCI NIH HHS3223-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC3434981biostudies-literatureUnknown30(26)<h4>Purpose</h4>Major concerns surround combining chemotherapy with bevacizumab in patients with colon cancer presenting with an asymptomatic intact primary tumor (IPT) and synchronous yet unresectable metastatic disease. Surgical resection of asymptomatic IPT is controversial.<h4>Patients and methods</h4>Eligibility for this prospective, multicenter phase II trial included Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1, asymptomatic IPT, and unresectable metastases. All received infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) combined with bevacizumab. The primary end point was major morbidity events, defined as surgical resection because of symptoms at or death related to the IPT. A 25% major morbidity rate was considered acceptable. Secondary end poiJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrimary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.PMC3434981U24 CA114732U10 CA037377U10 CA012027U10 CA069974U10 CA069651McCahill LEWagman LDO'Connell MJGiguere JKDakhil SRFehrenbacher LSharif SPetrelli NJLai LLLopa SHBechar NWolmark NYothers GfalsePrimary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.<h4>Purpose</h4>Major concerns surround combining chemotherapy with bevacizumab in patients with colon cancer presenting with an asymptomatic intact primary tumor (IPT) and synchronous yet unresectable metastatic disease. Surgical resection of asymptomatic IPT is controversial.<h4>Patients and methods</h4>Eligibility for this prospective, multicenter phase II trial included Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1, asymptomatic IPT, and unresectable metastases. All received infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) combined with bevacizumab. The primary end point was major morbidity events, defined as surgical resection because of symptoms at or death related to the IPT. A 25% major morbidity rate was considered acceptable. Secondary end poi2012-01-01T00:00:00Z2012 Sep2026-05-02T04:15:30.543Z2019-03-27T00:57:32ZS-EPMC34349812286988810.1200/JCO.2012.42.404410.1200/jco.2012.42.4044